Roses Bhadramans
- Akero Therapeutics (Nasdaq:Acro) is above ~ 5% On Friday after trading hours after announced that he would hold a conference call on January 27 to discuss the results of the Stage 2B Efruxifermina Phase Testing in Patients with Compensated Cyrosis of the liver due to metabolism
